Impact of right atrial-left ventricular dual-chamber permanent pacing in patients with severely symptomatic hypertrophic obstructive cardiomyopathy

Circulation Journal

Volumn 69, Issue 5, 2005, Pages 536-542

  Honda, Toshihiro ^a   Shono, Hiroyuki ^a   Koyama, Junjiro ^a   Tsuchiya, Takeshi ^b   Hayashi, Masamichi ^a   Hirayama, Toitsu ^a   Uesugi, Hideyuki ^a   Honda, Takashi ^a  

^a SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^b Hakuaikai Hospital   (Japan)

Author keywords

Dual chamber pacing; Hypertrophic obstructive cardiomyopathy; Midventricular obstruction; Outflow obstruction

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DISOPYRAMIDE;

ADULT; AGED; AORTA PRESSURE; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM PACING; HEART CATHETERIZATION; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART THORAX INDEX; HEART VENTRICLE PACING; HEART VENTRICULOGRAPHY; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; PHYSICAL EXAMINATION; PLEURA EFFUSION; PRESSURE GRADIENT; STATISTICAL ANALYSIS; THORAX RADIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AGED; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIA; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; PACEMAKER, ARTIFICIAL; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION; VENTRICULAR FUNCTION, LEFT;

EID: 19744376544     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.536     Document Type: Article

References (21)

1. Fananapazir L, McAreavey D. Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 1998; 31: 259-264.
2. Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodana K, et al. Class Ia antiarrhythmic drug, cibenzoline: A new approach to medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 1520-1524.
3. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999; 47: 94-100.
4. Tsuchikane E, Takeda Y, Kobayashi T, Yachiku K, Nasu K, Kobayashi Y, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Initial and follow-up results in the first 27 patients. Circ J 2003; 67: 763-767.
5. Hirata K, Wake M, Asato H, Kyushima M, Serizawa Y. Sudden death of a case of hypertrophic obstructive cardiomyopathy 19 months after successful percutaneous transluminal septal myocardial ablation. Circ J 2003; 67: 559-561.
6. Qin JX, Shiota T, Lever HM, Asher CR, Popovic ZB, Greenberg NL, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction intervention. Am J Cardiol 2004; 93: 171-175.
7. Maron BJ. Hypertrophic cardiomyopathy: A systemic review. JAMA 2002; 287: 1308-1320.
8. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
9. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992; 339: 1318-1323.
10. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994; 90: 2731-2742.
11. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double-blind, crossover trial. J Am Coll Cardiol 1997; 29: 435-441.
12. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS for the M-PATHY Study Investigators. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: A randomized, double-blind, crossover study (M-PATHY). Circulation 1999; 99: 2927-2933.
13. Linde C, Gadler F, Kappenberger L, Ryden L for the PIC study group. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Am J Cardiol 1999; 83: 903-907.
14. Chang AC, Atiga WL, McAreavey D, Fananapazir L. Relief of left ventricular outflow tract obstruction following inadvertent left ventricular apical pacing in a patient with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1995; 18: 1450-1454.
15. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, Oda H, et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996; 28: 1234-1242.
16. Gadler F, Linde C, Juhlin-Dannfeldt A, Ribeiro A, Ryden L. Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996; 27: 1219-1224.
17. Briguori C, Betocchi S, Manganelli F, Gigante B, Losi MA, Ciampi Q, et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. Eur Heart J 2001; 22: 1328-1336.
18. Pak PH, Maughan WL, Baughman KL, Kieval RS, Kass DA. Mechanisms of acute mechanical benefit from VDD pacing in hypertrophied heart: Similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation 1998; 98: 242-248.
19. Fighali S, Krajcer Z, Edelman S, Leachman RD. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: Higher incidence in patients with midventricular obstruction. J Am Coll Cardiol 1987; 9: 288-294.
20. Ishiwata S, Nishiyama S, Nakanishi S, Seki A. Two types of left ventricular wall motion abnormalities with distinct clinical features in patients with hypertrophic cariomyopathy. Eur Heart J 1993; 14: 1629-1639.
21. Bristou MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al for the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.